Triptans

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998 Källén (control unexposed, disease free), 2011 Nezvalová-Henriksen (Control unexposed, sick), 2013 Spielmann (Control unexposed, disease free), 2017 40.99[0.85; 1.15]57,1464,397not evaluable Major congenital malformations Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998 Källén (control unexposed, disease free), 2011 Nezvalová-Henriksen (Control unexposed, sick), 2013 Spielmann (Control unexposed, disease free), 2017 40.97[0.81; 1.17]39,0574,392not evaluable Congenital heart defects Källén (control unexposed, disease free), 2011 de Jonge - Sumatriptan, 2013 21.32[0.61; 2.88]13,7072,839not evaluable Chromosomal abnormalities Spielmann (Control unexposed, disease free), 2017 11.18[0.44; 3.17]25325not evaluable Limb defects de Jonge - Sumatriptan, 2013 11.37[0.08; 22.33]18458not evaluable Minor congenital malformations O'Quinn - Sumatriptan, 1999 Spielmann (Control unexposed, disease free), 2017 20.68[0.06; 8.05]46387not evaluable Nervous system anomalies de Jonge - Sumatriptan, 2013 11.22[0.07; 19.75]20858not evaluable Oro-facial clefts de Jonge - Sumatriptan, 2013 10.86[0.05; 13.97]29458not evaluable Digestive system anomalies de Jonge - Sumatriptan, 2013 10.70[0.04; 11.34]36258not evaluable Eye defects 0----- Genital anomalies de Jonge - Sumatriptan, 2013 10.81[0.05; 13.08]31458not evaluable Respiratory system anomalies de Jonge - Sumatriptan, 2013 14.57[0.28; 74.87]5558not evaluable Urinary malformations 0----- Abdominal wall defects 0----- Cardiac septal defects Källén (control unexposed, disease free), 2011 11.08[0.67; 1.74]6,7922,777not evaluable Ear, face and neck anomalies 0----- Gastroschisis Werler, 2009 10.80[0.10; 6.38]5149not evaluable Other anomalies/syndromes (non chromosomal) 0----- Growth parameters and prematurity Preterm (< 37 weeks) Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998 Olesen - Sumatriptan (Control unexposed, sick), 2000 Källén (control unexposed, disease free), 2011 Bérard, 2012 Nezvalová-Henriksen (Control unexposed, sick), 2013 Wood 2016a (Control exposed only before pregnancy), 2016 Spielmann (Control unexposed, disease free), 2017 71.03[0.71; 1.48]4,4702,480not evaluable Low birth weight (< 2500g) Olesen - Sumatriptan (Control unexposed, sick), 2000 Kallen - Sumatriptan, 2001 Bérard, 2012 Nezvalová-Henriksen (Control unexposed, sick), 2013 Wood 2016a (Control exposed only before pregnancy), 2016 50.92[0.71; 1.19]3,5782,692not evaluable Small for gestational age (weight) Nezvalová-Henriksen (Control unexposed, sick), 2013 Wood 2016a (Control exposed only before pregnancy), 2016 21.08[0.85; 1.38]2991,861not evaluable Very low birth weight (< 1500g) Kallen - Sumatriptan, 2001 10.73[0.10; 5.40]-658not evaluable Maternal consequences Preeclampsia Nezvalová-Henriksen (Control unexposed, sick), 2013 Wood 2016a (Control exposed only before pregnancy), 2016 Spielmann (Control unexposed, disease free), 2017 31.25[0.73; 2.14]2752,183not evaluable Abruptio placentae Spielmann (Control unexposed, disease free), 2017 12.80[0.60; 13.08]9432not evaluable Caesarean Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998 11.53[0.74; 3.16]3880not evaluable Gestational diabete Nezvalová-Henriksen (Control unexposed, sick), 2013 10.75[0.33; 1.67]241,465not evaluable Postpartum hemorrhage Nezvalová-Henriksen (Control unexposed, sick), 2013 10.69[0.44; 1.09]219185not evaluable Neonatal disorders Low Apgar score (< 7) (at 5 min) Wood 2016a (Control exposed only before pregnancy), 2016 11.52[0.52; 4.41]14396not evaluable Neonatal medical care Nezvalová-Henriksen (Control unexposed, sick), 2013 10.77[0.45; 1.33]136185not evaluable Intrauterine deaths Early intrauterine death (< 22 weeks) Shuhaiber - Sumatriptan (Control unexposed, disease free), 1998 O'Quinn - Sumatriptan, 1999 Bérard, 2012 Spielmann (Control unexposed, disease free), 2017 41.64[0.94; 2.86]5,012686not evaluable Elective/induced termination of pregnancy O'Quinn - Sumatriptan, 1999 Spielmann (Control unexposed, disease free), 2017 21.11[0.42; 2.98]108508not evaluable Late intrauterine deaths (> 22 weeks) O'Quinn - Sumatriptan, 1999 Spielmann (Control unexposed, disease free), 2017 20.65[0.11; 3.86]7508not evaluable Ectopic pregnancy O'Quinn - Sumatriptan, 1999 11.21[0.07; 19.73]276not evaluable Intrauterine deaths (as a whole or unspecified) Nezvalová-Henriksen (Control unexposed, disease free), 2013 11.01[0.56; 1.83]--not evaluable Perinatal death Kallen - Sumatriptan, 2001 11.23[0.40; 3.80]-658not evaluable0.0100.01.0